IMR Press / EJGO / Volume 37 / Issue 2 / DOI: 10.12892/ejgo2804.2016

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status in ovarian cancer
Show Less
1 Department of Obstetrics and Gynecology, Provincial Hospital, Affiliated to Anhui Medical University, Hefei, China
2 Department of Obstetrics and Gynecology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Eur. J. Gynaecol. Oncol. 2016, 37(2), 204–210;
Published: 10 April 2016

Purpose: Ovarian cancer is the most deadly of all gynecologic malignancies, due in part to the diagnosis at an advanced stage caused by the deficiency of specific marks and symptoms, by the absence of reliable tests for screening, and by early detection. Materials and Methods: Insulin-like growth factor-I (IGF-I) is known to be involved in the development and promotion of diverse examples of solid tumors including ovarian cancer. IGF-I levels in local tissue are subject to both endocrine and paracrine/autocrine regulation. Results: Most patients will react initially to treatment, but almost 70% of them will have a recurrence. Consequently, new therapeutic modalities are urgently required to overcome chemoresistance observed in ovarian cancer patients. IGF-1R expression was evaluated immunohistochemically in tissue microarray blocks constructed from 1,200 ovarian cancer samples collected from three medical institutions. Conclusion: Evidence accumulates suggesting that the insulin/insulin growth factor (IGF) pathways could play a good therapeutic target in various cancers, including ovarian cancer.
Insulin-like growth factor-1 receptor (IGF1-R)
Ovarian cancer
Back to top